<DOC>
	<DOCNO>NCT02524782</DOCNO>
	<brief_summary>A Phase 1 , combine Single Ascending Dose ( SAD ) Multiple-ascending Dose ( MAD ) study evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) MEDI4166 Subjects Type 2 Diabetes Mellitus ( T2D ) .</brief_summary>
	<brief_title>A Phase 1 , Single- Multiple Dose Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics MEDI4166 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description>This study first time human ( FTIH ) , Phase 1 , randomize , double-blind study evaluate safety , tolerability , PK , PD MEDI4166 administer single multiple ascend dos subject T2D .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 Diabetes , age 1865 Must provide write informed consent BMI &gt; =25 = &lt; 42 Venous access suitable multiple cannulation Vital sign within normal specified range Females must nonlactating nonchildbearing potential Males must practice 2 effective contraceptive measure sexually active Any concurrent condition opinion investigator would interfere evaluation investigational product History presence gastrointestinal , renal , hepatic disease condition know interfere absorption , distribution , metabolism , excretion drug History cancer , exception basal cell carcinoma carcinoma cervix Any clinically important illness , medical/surgical procedure , trauma within 4 week prior dose Positive Hepatitis B , Hepatitis C HIV test use antiretroviral medication screen Current previous use systemic corticosteroid within past 28 day prior screen Use medicinal product herbal preparation license weight loss prohibit . Positive drug screen Type 1 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MEDI-4166 , diabetes</keyword>
</DOC>